Exelixis, Inc. (EXEL) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Wait for pullback to $44.81. Weak momentum — blocks BUY_NOW at $49.24. Engine's entry $44.81 (50-day MA) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: CABOMETYX; Analyst target reached - limited upside remaining.
Exelixis is an oncology company with four marketed products; CABOMETYX and COMETRIQ (both cabozantinib formulations) generated $2,122.8M in 2025 net product revenues, up 17% year-over-year. Revenue comes from U.S. product sales and ex-U.S. royalties from partners Ipsen and... Read more
Wait for pullback to $44.81. Weak momentum — blocks BUY_NOW at $49.24. Engine's entry $44.81 (50-day MA) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: CABOMETYX; Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.28, quality 8.7/10, growth 7.5/10). Score 6.3/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 76d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent Developments — Exelixis, Inc.
Latest news
- Exelixis (EXEL) is a top-ranked value stock: Should you buy? - MSN — MSN positive
- Will Exelixis (EXEL) beat estimates again in its next earnings report? - MSN — MSN positive
- EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study - TradingView — TradingView positive
- Exelixis Posts Strong Q1 Results, Expands Share Buybacks - The Globe and Mail — The Globe and Mail positive
- EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus - TradingView — TradingView positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductCABOMETYX10-K Item 1A: 'Our ability to grow our company is dependent upon the commercial success of CABOMETYX in its approved indications'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $44.81. Weak momentum — blocks BUY_NOW at $49.24. Engine's entry $44.81 (50-day MA) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: CABOMETYX; Analyst target reached - limited upside remaining. Chart setup: Golden cross, above all MAs, RSI 65, MACD bullish. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.28, quality 8.7/10, growth 7.5/10). Target $50.60 (+2.8%), stop $42.20 (−16.7%), Setup A.R:R 2.2:1. Score 6.3/10, moderate confidence.
Take-profit target: $50.60 (+12.9% upside). Target $50.60 (+2.8%), stop $42.20 (−16.7%), Setup A.R:R 2.2:1. Stop-loss: $42.20.
Concentration risk — Product: CABOMETYX; Analyst target reached - limited upside remaining; Near 52-week high (4.0% away).
Exelixis, Inc. trades at a P/E of 16.1 (forward 12.0). TrendMatrix value score: 7.0/10. Verdict: Buy (Wait for Entry).
26 analysts cover EXEL with a consensus score of 3.8/5. Average price target: $49.
What does Exelixis, Inc. do?Exelixis is an oncology company with four marketed products; CABOMETYX and COMETRIQ (both cabozantinib formulations)...
Exelixis is an oncology company with four marketed products; CABOMETYX and COMETRIQ (both cabozantinib formulations) generated $2,122.8M in 2025 net product revenues, up 17% year-over-year. Revenue comes from U.S. product sales and ex-U.S. royalties from partners Ipsen and Takeda. Lead pipeline asset zanzalintinib is under FDA review for colorectal cancer.